The biopharmaceutical industry is committed to advancing solutions for a competitive, value-based health care system that makes better use of today’s medicines and fosters the development of tomorrow’s cures. The President’s budget goes in the opposite direction by including harmful and misguided proposals that would hurt patients and stifle innovation.
Once again, new research is pointing to the critical need to reform the 340B program. The latest data, from Berkeley Research Group (BRG), uncovered startling differences in Medicare Part B hospital outpatient reimbursements in 340B hospitals verses non-340B hospitals. Released by the Alliance for Integrity and Reform of 340B (PhRMA is a coalition member), the research found that 340B hospitals account for 61 percent of Part B drug reimbursements to hospitals but slightly less than half of total Medicare hospital outpatient revenue, and 340B hospitals are driving most of the overall growth in Part B reimbursement. Thoughtful reform is needed to address the distortions being created by the 340B program.
Last week, we highlighted how changing the structure of the Medicare Part D program would cause more harm than good by restricting beneficiary access to needed medicines.
Here’s a look at what is being said about harmful proposals to change the structure of the Part D program:
- “[I]f you talk to experts who study the pharmaceutical market in the United States, they aren’t optimistic that, by itself, letting the government play drug negotiator would take a big bite out of prescription drug spending,” the New York Times – The Upshot reported last week.
Diagnosed with type 1 diabetes at a young age, five-year-old Rhys has not let his diagnosis be his destiny. He enjoys life to the fullest, from playing sports to having treats at a friend’s birthday party.
Fifteen years ago, Jamie was diagnosed with a rare blood cancer and thought she would not live to see her son grow up. Today, she’s happy, strong and planning a long-delayed trip to Paris with her husband.
Solving the world’s toughest health problems takes decades of research, but it also takes hope and courage from researchers. Jen, a biopharmaceutical scientist specializing in oncology, wakes up every day working to find new treatments and cures for patients.
Intellectual property drives and sustains research, development and delivery of valuable new treatments and cures for patients who need them around the world. America’s world-leading research-based biopharmaceutical industry supports 3.4 million good-paying jobs in all 50 states. With this in mind, PhRMA takes the annual opportunity to submit our comments to the Office of the U.S. Trade Representative’s (USTR) Special 301 Report– a regular review of trade barriers that exist with U.S. trading partners.
More than 1.7 million new cancer cases are expected to be diagnosed in the United States this year. Although that number is daunting, World Cancer Day reminds us that tremendous progress in the prevention and treatment of cancer has been made over the years, and researchers around the globe are working together to advance cancer care for patients.
We previously noted that it is counterintuitive that more hospitals would become eligible for the 340B discount program as the share of uninsured patients these hospitals serve declines due to the coverage expansions in the Affordable Care Act.
Now, new data reported by hospitals shows the recent declines in the uninsured are translating into less uncompensated care for hospitals. If the number of uninsured is declining and uncompensated care is declining, why is the 340B program continuing to grow? This raises important questions about whether the current hospital eligibility criteria for 340B are consistent with the program’s origins as a discount program to safety net facilities.
This week on Medicare Monday, we’re looking at how proposals to change the structure of Medicare Part D could actually limit – and hurt – beneficiary access.
As we’ve covered before, price negotiation already occurs effectively within the Medicare prescription drug program. Large, powerful Part D purchasers negotiate discounts and rebates directly with manufacturers, and according to the Government Accountability Office, this private negotiation helps keep costs low for both beneficiaries and taxpayers. In fact, the Medicare Trustees have reported rebates are substantial and have increased each year of the program.
Record number of new medicines in 2015: The FDA’s Center for Drug Evaluation and Research’s (CDER) fifth annual Novel New Drugs Summary approved a record 45 new medicines in 2015, marking the highest number of approvals in almost two decades. More than a third of the medicines approved were first-in-class treatment options - offering a completely new way to treat disease – and nearly half were for the treatment of rare disease. Learn more about how these and other new medicines are giving patients even greater hope for the future.
Topics: Week in Review
A couple of weeks ago, we talked about the success of the Medicare prescription drug program 10 years after its implementation, and over the coming weeks, we’ll continue to look at coverage before and after the program.
One example is how the implementation of Part D expanded coverage to millions of seniors who previously didn’t have access to comprehensive drug coverage.